By Dominic Chopping
Novo Nordisk is gradually expanding supply capacity for its blockbuster weight-loss drug, but said it will continue to limit supply of lower-strength doses of the Wegovy medicine in the U.S. as it seeks to safeguard supplies.
Write to Dominic Chopping at [email protected]
Read the full article here